Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment

S. Chiara, E. Campora, C. Simoni, M. Confalonieri, M. Psilogenis, R. Rosso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Forty-three untreated cancer patients receiving moderately emetogenic polychemotherapy entered a phase II trial in order to evaluate the effectiveness of the combination of metoclopramide (40 mg every 6 hrs) and dexamethasone (8 mg every 12 hrs) in the prevention of delayed emesis (days 2-3). For the control of acute emesis all patients received on day 1 ondansetron 8 mg for 3 times. Results of antiemetic treatment were as follows: complete/major protection from acute emesis (day 1) was observed in 72%/88% of patients. Worst day analysis of delayed emesis (days 2 and 3) showed that complete/major protection was obtained in 93%/95% of cases, respectively. Delayed nausea was not as well controlled: complete/major protection was observed in 44%/79% of patients. Extrapyramidal reactions occurred in 3 patients and moderate epigastric pain was reported by 3 patients. Since control of acute emesis could be one of the most important factors influencing delayed emesis, the absence of acute symptoms in 72% of our patients may be partially responsible for the excellent control of delayed emesis. The combination of metoclopramide and dexamethasone is a feasible and effective treatment for delayed emesis in outpatients receiving moderately emetogenic chemotherapy.

Original languageEnglish
Pages (from-to)1597-1599
Number of pages3
JournalAnticancer Research
Volume15
Issue number4
Publication statusPublished - 1995

Fingerprint

Metoclopramide
Dexamethasone
Vomiting
Therapeutics
Ondansetron
Antiemetics
Combination Drug Therapy
Nausea
Outpatients
Drug Therapy
Pain

Keywords

  • Delayed emesis
  • Dexamethasone
  • Metoclopramide
  • Moderately emetogenic chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment. / Chiara, S.; Campora, E.; Simoni, C.; Confalonieri, M.; Psilogenis, M.; Rosso, R.

In: Anticancer Research, Vol. 15, No. 4, 1995, p. 1597-1599.

Research output: Contribution to journalArticle

Chiara, S, Campora, E, Simoni, C, Confalonieri, M, Psilogenis, M & Rosso, R 1995, 'Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment', Anticancer Research, vol. 15, no. 4, pp. 1597-1599.
Chiara, S. ; Campora, E. ; Simoni, C. ; Confalonieri, M. ; Psilogenis, M. ; Rosso, R. / Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment. In: Anticancer Research. 1995 ; Vol. 15, No. 4. pp. 1597-1599.
@article{a5cc4a6a2c164d3b87239cd441f95983,
title = "Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment",
abstract = "Forty-three untreated cancer patients receiving moderately emetogenic polychemotherapy entered a phase II trial in order to evaluate the effectiveness of the combination of metoclopramide (40 mg every 6 hrs) and dexamethasone (8 mg every 12 hrs) in the prevention of delayed emesis (days 2-3). For the control of acute emesis all patients received on day 1 ondansetron 8 mg for 3 times. Results of antiemetic treatment were as follows: complete/major protection from acute emesis (day 1) was observed in 72{\%}/88{\%} of patients. Worst day analysis of delayed emesis (days 2 and 3) showed that complete/major protection was obtained in 93{\%}/95{\%} of cases, respectively. Delayed nausea was not as well controlled: complete/major protection was observed in 44{\%}/79{\%} of patients. Extrapyramidal reactions occurred in 3 patients and moderate epigastric pain was reported by 3 patients. Since control of acute emesis could be one of the most important factors influencing delayed emesis, the absence of acute symptoms in 72{\%} of our patients may be partially responsible for the excellent control of delayed emesis. The combination of metoclopramide and dexamethasone is a feasible and effective treatment for delayed emesis in outpatients receiving moderately emetogenic chemotherapy.",
keywords = "Delayed emesis, Dexamethasone, Metoclopramide, Moderately emetogenic chemotherapy",
author = "S. Chiara and E. Campora and C. Simoni and M. Confalonieri and M. Psilogenis and R. Rosso",
year = "1995",
language = "English",
volume = "15",
pages = "1597--1599",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment

AU - Chiara, S.

AU - Campora, E.

AU - Simoni, C.

AU - Confalonieri, M.

AU - Psilogenis, M.

AU - Rosso, R.

PY - 1995

Y1 - 1995

N2 - Forty-three untreated cancer patients receiving moderately emetogenic polychemotherapy entered a phase II trial in order to evaluate the effectiveness of the combination of metoclopramide (40 mg every 6 hrs) and dexamethasone (8 mg every 12 hrs) in the prevention of delayed emesis (days 2-3). For the control of acute emesis all patients received on day 1 ondansetron 8 mg for 3 times. Results of antiemetic treatment were as follows: complete/major protection from acute emesis (day 1) was observed in 72%/88% of patients. Worst day analysis of delayed emesis (days 2 and 3) showed that complete/major protection was obtained in 93%/95% of cases, respectively. Delayed nausea was not as well controlled: complete/major protection was observed in 44%/79% of patients. Extrapyramidal reactions occurred in 3 patients and moderate epigastric pain was reported by 3 patients. Since control of acute emesis could be one of the most important factors influencing delayed emesis, the absence of acute symptoms in 72% of our patients may be partially responsible for the excellent control of delayed emesis. The combination of metoclopramide and dexamethasone is a feasible and effective treatment for delayed emesis in outpatients receiving moderately emetogenic chemotherapy.

AB - Forty-three untreated cancer patients receiving moderately emetogenic polychemotherapy entered a phase II trial in order to evaluate the effectiveness of the combination of metoclopramide (40 mg every 6 hrs) and dexamethasone (8 mg every 12 hrs) in the prevention of delayed emesis (days 2-3). For the control of acute emesis all patients received on day 1 ondansetron 8 mg for 3 times. Results of antiemetic treatment were as follows: complete/major protection from acute emesis (day 1) was observed in 72%/88% of patients. Worst day analysis of delayed emesis (days 2 and 3) showed that complete/major protection was obtained in 93%/95% of cases, respectively. Delayed nausea was not as well controlled: complete/major protection was observed in 44%/79% of patients. Extrapyramidal reactions occurred in 3 patients and moderate epigastric pain was reported by 3 patients. Since control of acute emesis could be one of the most important factors influencing delayed emesis, the absence of acute symptoms in 72% of our patients may be partially responsible for the excellent control of delayed emesis. The combination of metoclopramide and dexamethasone is a feasible and effective treatment for delayed emesis in outpatients receiving moderately emetogenic chemotherapy.

KW - Delayed emesis

KW - Dexamethasone

KW - Metoclopramide

KW - Moderately emetogenic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0028817475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028817475&partnerID=8YFLogxK

M3 - Article

C2 - 7654054

AN - SCOPUS:0028817475

VL - 15

SP - 1597

EP - 1599

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -